Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells  by Dravis, Christopher et al.
ArticleSox10Regulates Stem/Progenitor andMesenchymal
Cell States in Mammary Epithelial CellsGraphical AbstractHighlightsd Sox10 labels and contributes to stem/progenitor activity in
mammary cells
d Sox10 drives EMT and delamination of clonogenic mammary
cells at high levels
d Sox10 expression and functional output are regulated by FGF
signaling
d Stem- and EMT-like breast cancers show the highest
expression levels of Sox10Dravis et al., 2015, Cell Reports 12, 2035–2048
September 29, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.08.040Authors
Christopher Dravis, Benjamin T. Spike,
J. Chuck Harrell, ...,
E. Michelle Southard- Smith,
Charles M. Perou, Geoffrey M. Wahl
Correspondence
wahl@salk.edu
In Brief
Dravis et al. report that Sox10 is
specifically expressed in either stem-cell-
or mesenchymal-like human breast
cancers. The authors then demonstrate
Sox10 can separately promote both
stem/progenitor and mesenchymal-like
states in mammary cells. They further
identify FGF signaling as a key extrinsic
mediator of Sox10 expression and
function.Accession NumbersGSE71300
Cell Reports
ArticleSox10 Regulates Stem/Progenitor and Mesenchymal
Cell States in Mammary Epithelial Cells
Christopher Dravis,1 Benjamin T. Spike,1 J. Chuck Harrell,2 Claire Johns,1 Christy L. Trejo,1 E. Michelle Southard-Smith,3
Charles M. Perou,4 and Geoffrey M. Wahl1,*
1Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA
2Department of Pathology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
3Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
4Departments of Genetics and Pathology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill,
NC 27599, USA
*Correspondence: wahl@salk.edu
http://dx.doi.org/10.1016/j.celrep.2015.08.040
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
To discover mechanisms that mediate plasticity in
mammary cells, we characterized signaling networks
that are present in the mammary stem cells respon-
sible for fetal and adult mammary development.
These analyses identified a signaling axis between
FGF signaling and the transcription factor Sox10.
Here, we show that Sox10 is specifically expressed
in mammary cells exhibiting the highest levels of
stem/progenitor activity. This includes fetal and adult
mammary cells in vivo and mammary organoids
in vitro. Sox10 is functionally relevant, as its deletion
reduces stem/progenitor competence whereas its
overexpression increases stem/progenitor activity.
Intriguingly, we also show that Sox10 overexpression
causes mammary cells to undergo a mesenchymal
transition. Consistent with these findings, Sox10
is preferentially expressed in stem- and mesen-
chymal-like breast cancers. These results demon-
strate a signaling mechanism through which stem
and mesenchymal states are acquired in mammary
cells and suggest therapeutic avenues in breast can-
cers for which targeted therapies are currently un-
available.INTRODUCTION
The capacity to reprogram differentiated cells in vivo and ex vivo
indicates that the differentiated state is not as fixed as once
thought (Takahashi and Yamanaka, 2006; Tata et al., 2013).
This plasticity has important implications for cancer, where the
dysregulation of stem and mesenchymal states appears to be
critical in disease initiation and progression. Phenotypic lability
may endow some types of cancer cells, often termed ‘‘cancer
stem cells’’ (CSC), with a greater capacity to propagate the dis-
ease when assayed in a transplant setting (Al-Hajj et al., 2003;
Bonnet and Dick, 1997). In contrast to CSCs, which typicallyCell Repexhibit mesenchymal characteristics, transcriptome analyses
have revealed another class of tumorigenic cancer cells whose
gene expression profiles resemble those of cells with known
stem or progenitor cell functions. Tumors with these distinct
‘‘stem-like’’ cancer cells tend to appear less differentiated and
behave more aggressively, while eliminating such cells can
attenuate tumor progression (Chen et al., 2012; Eppert et al.,
2011; Merlos-Sua´rez et al., 2011; Schepers et al., 2012). Stem-
like cancer cells may arise either by cell of origin, in which the
tumor originates in a stem/progenitor cell and retains those
properties through tumorigenesis, or through reprogramming
of differentiated cells into a stem-like state (Barker et al., 2009;
Schwitalla et al., 2013). Because a significant fraction of triple-
negative breast cancers contain stem-like cancer cells, we
have focused on elucidating the molecular mechanisms that
specify the mammary stem cell (MaSC) state, assuming that
such knowledge will deepen our understanding of how such
breast cancers initiate and progress.
The mammary gland contains at least two populations of cells
with stem or progenitor qualities (Shackleton et al., 2006; Stingl
et al., 2006). Luminal progenitors comprise a heterogeneous
population of cells in the luminal fraction of the gland that
possess clonogenic properties in vitro (Shehata et al., 2012).
This population may contain the cell of origin for stem-like
basal-like breast cancers (Lim et al., 2009). Transplantation
studies also demonstrate that the basal fraction of the gland con-
tains cells capable of generating an entire mammary gland.
These MaSCs are inferred to possess extensive proliferative,
invasive, and multi-lineage differentiation potential, as a single
MaSC can regenerate a functional gland (Shackleton et al.,
2006).
Several fundamental aspects of MaSC biology remain to be
elucidated. There is no consensus on the number of MaSCs
within the gland, which has hindered analyses of the origin of
breast tumors (Tomasetti and Vogelstein, 2015). There are also
conflicting data about the topographical location of MaSCs in
the gland and the developmental timeframe during which these
cells retain multi-lineage potential (Rios et al., 2014; Van Key-
meulen et al., 2011). Both of these problems might be resolved
by availability of markers enabling prospective MaSC identifica-
tion. The mechanisms by which mammary cells enter and exitorts 12, 2035–2048, September 29, 2015 ª2015 The Authors 2035
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from theMaSC state also remain to be defined, and resolving this
problem may present solutions to those concerning MaSC iden-
tification. One recent advance on this topic involves the demon-
stration that Sox9 and Slug act together to convert mammary
epithelial cells into cells with MaSC-like properties (Guo et al.,
2012). However, the degree to which this mechanism is utilized
in the gland is not clear because the distribution and function
of Sox9 or Sox9/Slug cells in unperturbed in vivo contexts remain
to be defined. Moreover, mice that are deficient for Slug do form
a complete native mammary gland, which suggests that Slug is
not an essential determinant of the MaSC state (Nassour et al.,
2012). Clearly, a better understanding of the transcriptional pro-
grams and extrinsic signaling mechanisms that regulate the
MaSC state is required.
To investigate the biology of MaSCs and MaSC-like cells in
cancer, our research has focused on the stem cells present dur-
ing fetal mammary development. During mid-late embryogen-
esis, mammary cells are highly proliferative and invasive and
likely experience conditions such as hypoxia and growth-ori-
ented metabolism that resemble those encountered by tumor
cells (Masson and Ratcliffe, 2014). Fetal MaSCs (fMaSCs) may
therefore most resemble theMaSC-like cancer cells in breast tu-
mors. Indeed, we previously showed that fMaSCs exhibit both
the organoid-forming and mammary-repopulating properties
found in luminal progenitors and adult MaSCs, respectively
(Spike et al., 2012). Transcriptome profiling of fMaSCs and adult
MaSCs revealed that the fMaSC signature gene list is uniquely
enriched in basal-like breast tumors, indicating the presence of
fMaSC-like cells in such tumors. This shared biology suggests
that fetal mammary development and fMaSCs can be utilized
to identify molecular mechanisms that govern important func-
tions in breast cancer.
Here, we describe how analysis of fMaSCs revealed an impor-
tant function for Sox10 in mammary cells. Sox family transcrip-
tion factors have well-defined roles in regulating cell-fate
decisions in different tissues and at different stages of develop-
ment (Sarkar and Hochedlinger, 2013). Sox factors generally
induce preferential differentiation down one cell lineage path
over another, often by antagonizing the activity of other line-
age-specifying factors. This phenomenon has best been
described with Sox2 and the elucidation of roles for Sox2 in mul-
tiple different cell-fate decisions, each of which occurs in concert
with other transcription factors (Sarkar and Hochedlinger, 2013).
However, when Sox expression or activity is balanced or kept at
lower levels in the cell by other key factors, differentiation is fore-
stalled and stem and progenitor functions arise (Kopp et al.,
2008). This is consistent with an emerging model of stem cellFigure 1. Sox10 Is an fMaSC- and Tumor-Associated Transcription Fa
(A) Log2 microarray expression values for Sox10 and FGF signaling molecules in
(B) E18 fMaSCs grown in 3D culture conditions for 5–7 days with the indicated m
(C) Sox10 mRNA expression levels in fMaSC-derived organoids grown with FGF
(D) FACS-based quantification of Venus+ cells in 7-day-old FGFRi-treated orga
genitors. Y axis represents the # of Venus+ cells as a % of the total # of cells in
(E) FACS-based quantification of Venus+ cells in 8-day-old organoids grown fr
fluorescence, and the number in the box is % gated Sox10+ cells.
(F) Whisker plots for Sox10 expression from the Metabric and UNC885 breast tum
from a particular tumor.
Error bars represent SD.
Cell Repspecification through the balance of lineage specifiers (Loh
and Lim, 2011). Sox factors can thus be mediators and markers
of both differentiation and stemness, depending on expression
level and cellular context.
Here, we report that Sox10 plays important regulatory roles in
promoting both stem- and epithelial to mesenchymal transition
(EMT)-like properties in mammary stem cells. Critically, these
stem and mesenchymal states are acquired independently of
one another; this clear distinction prevents potential conflation
of stem cell and mesenchymal properties, and demonstrates
how these distinct states can be related by a single factor such
as Sox10. We further present evidence that these functions
may be conserved in certain types of aggressive breast cancers,
and demonstrate the importance of FGF10 in a paracrine
signaling mechanism that regulates Sox10.
RESULTS
Sox10 Is an fMaSC- and Tumor-Associated
Transcription Factor Regulated by Fibroblast Growth
Factor Signaling
To identify molecular mechanisms that specify stem/progenitor
cell functions in mammary cells, we analyzed transcriptome
profiles of fMaSCs and their surrounding fetal stroma (fStr)
(Spike et al., 2012). We prioritized both transcription factors
that are differentially expressed in the fMaSC-enriched popula-
tion and inferred signaling axes between fMaSCs and fStr
that could regulate their expression. These analyses identified
Sox10 as one of the most prominent transcription factors asso-
ciated with the fMaSC population (Figure 1A). This was of imme-
diate interest, as Sox family transcription factors play important
roles in pluripotent or tissue-specific stem cell states (Sarkar
and Hochedlinger, 2013). Further, Sox10 in particular has
been shown to be a critical transcription factor in reprogram-
ming differentiated cells into multipotent stem/progenitor states
(Hornig et al., 2013; Kim et al., 2014; Najm et al., 2013; Yang
et al., 2013).
These analyses also revealed high relative expression of
FGF7 and FGF10 in the fStr and expression of multiple fibro-
blast growth factor receptor (FGFR) family members in the
fMaSC population (Figure 1A). Fibroblast growth factor (FGF)
signaling plays a critical role in fetal mammary development,
and we previously showed that fMaSCs could utilize FGF
signaling to promote multipotent growth in vitro (Lu et al.,
2008; Mailleux et al., 2002; Spike et al., 2012). Furthermore,
FGF signaling has been shown to regulate the expression
and function of different Sox family transcription factors inctor Regulated by FGF Signaling
E18 fMaSCs and fStroma.
edia. Scale bar, 150 mm.
Ri for 7 days. Y axis represents Sox10 mRNA levels normalized to the vehicle.
noids grown from Sox10-H2BVenus fMaSCs or adult mammary luminal pro-
the primary organoids, normalized to the vehicle.
om E18 Sox10-H2BVenus fMaSCs in defined growth factors. x axis is Venus
or databases across multiple subtypes. Each dot is a Sox10 expression value
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Figure 2. Sox10 Is a Fetal Mammary Stem Cell Marker that Improves fMaSC Purification
(A) Whole-mount view of the one to three mammary rudiment pairs in an E18 Sox10-H2BVenus embryo.
(B and C) Venus fluorescence in E16 and E18 Sox10-H2BVenus mammary rudiments whole mounts.
(D) Whole-mount mammary rudiment from E18 Sox10-H2BVenus embryo immunostained with luminal (K8) and basal (K14) markers.
(E) FACS of E18 Sox10-H2BVenus fetal mammary cells (pre-gated for EpCAM+ cells).
(F) Keratin immunostain of single E18 Sox10flox-GFP EpCAM+ fetal mammary cells.
(legend continued on next page)
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multiple developing tissues through a feedback loop of un-
known mechanism (Chen et al., 2014; Seymour et al., 2012).
These observations led us to hypothesize that an FGF signaling
axis may regulate Sox10 expression in mammary stem/progen-
itor cells.
To address this, we grew fMaSCs in 3D culture conditions in
the presence of the pan-FGFR inhibitor, JNJ-42756493 (FGFRi).
With vehicle only, fMaSCs form organoids when either epidermal
growth factor (EGF) or basic FGF (FGF2) is added to the media
but fail to form organoids if neither growth factor is present (Fig-
ure 1B; Figure S1). The addition of FGFRi blocks organoid forma-
tion if FGF is the only available growth factor. However, organoid
formation is rescued upon adding EGF to media containing
FGFRi (Figure 1B). As the number of dead cells does not increase
in FGFRi-treated organoids (data not shown), these data demon-
strate that fMaSC-derived organoids can utilize FGF signaling
and indicate that FGFRi blocks FGF signaling without eliciting
overt cytotoxicity.
To determine if FGF signaling regulates Sox10 expression
in mammary cells, we measured Sox10 expression levels in
fMaSC-derived organoids plated with vehicle or increasing con-
centrations of FGFRi. Organoid exposure to FGFRi resulted in
significant dose-dependent decreases in Sox10 mRNA expres-
sion levels (Figure 1C). Similarly, by using a Sox10-H2BVenus
bacterial artificial chromosome (BAC) transgenic mouse line (in
which H2B-Venus is expressed under Sox10 transcriptional reg-
ulatory elements) to quantify the Sox10+ cells through Venus
fluorescence, we found that FGFRi exposure significantly
reduced the number of Sox10+ mammary organoid cells (Fig-
ure 1D). This effect was observed in a serum-based medium or
in a serum-free medium (SFM) containing defined growth factors
(Figure 1D; Figure S1). Organoids that were generated from adult
luminal progenitors also showed a reduction in Sox10+ cells
following FGFRi exposure (Figure 1D). fMaSCs grown in the
presence of SFM with EGF + FGF10 developed into organoids
with increased numbers of Sox10+ cells compared to fMaSCs
grown only in SFM with EGF (Figure 1E). This effect was not
seen in fMaSCs grown with SFM containing EGF + FGF2, indi-
cating a specific role for FGF10 signaling through its cognate re-
ceptor, FGFR2b. No significant differences in Sox10 levels were
observed in fMaSCs grown ± EGF (Figure S2). These data indi-
cate that FGF signaling specifically regulates Sox10 expression
levels in mammary cells.
To determine whether elevated Sox10 expression was a
feature common to fMaSCs and their associated human cancer
counterparts, we next analyzed the expression of Sox10 across
a panel of tumor samples representing two distinct breast
cancer datasets. This analysis revealed that basal-like and
claudin-low breast cancers tend to express significantly higher
levels of Sox10 than the other subtypes of the disease (Fig-(G) Efficiency of organoid formation from E18 Sox10-H2BVenus female mammar
plated.
(H) A bi-lineage organoid derived from fMaSCs.
(I) A reconstituted mammary gland following transplantation of Sox10+ fetal cells
(J) Sox10-H2BVenus-derived fMaSCs (columns 1 and 2), CD24/CD49f-derived fM
clustered (SAM: FDR < 0.01%) using previously indicated differentially expresse
Error bars represent SD.
Cell Repure 1F), in accordance with two recent studies of Sox10 in
breast cancer (Cimino-Mathews et al., 2013; Ivanov et al.,
2013). These two subtypes comprise the bulk of triple-negative
breast cancers, and both are frequently metastatic and aggres-
sive. However, they differ in that basal-like breast cancers are
weakly differentiated and the most fMaSC-like of the breast
cancer subtypes, while claudin-low breast cancers possess
the most EMT-like morphology and transcriptome among the
breast cancer subtypes (Prat et al., 2010; Spike et al., 2012).
These findings suggest that Sox10 expression may correlate
with distinct stem and mesenchymal properties in human
breast cancers.
Collectively, these data identify Sox10 as an FGF-responsive,
mammary stem cell-associated transcription factor with likely
roles in normal and transformed mammary cells.
Sox10 Is a Fetal Mammary Stem Cell Marker that
Improves fMaSC Purification
To elucidate the role of Sox10 in mammary cells, the Sox10-
H2BVenus BAC transgenic mouse line was used to visualize
Sox10+ cells. Consistent with the fMaSC transcriptome data,
Sox10was robustly expressed in all five fetal mammary rudiment
pairs (Figures 2A–2C). The rudiments at these stages appear to
be very primitive, as there is amorphous structure at embryonic
day 16 (E16), while at E18, the lumen has not yet formed and
there is no clear segregation of the luminal marker keratin-8
(K8) and the basal marker keratin-14 (K14) (Figure 2D).
Sox10+ fetal mammary cells were recovered using flow cy-
tometry for more detailed molecular characterization. As cells
in the rudiment can be distinguished from surrounding stromal
cells by the epithelial cell adhesion marker (EpCAM), fetal
Sox10+ mammary cells were isolated as Sox10+;EpCAM+.
Consistent with Figure 2C, nearly all cells appear to be Sox10+
within the rudiment by fluorescence-activated cell sorting
(FACS) analysis (Figure 2E). It is possible that the stability of
the H2B-Venus fusion protein may yield cells that no longer
express Sox10 but still retain the Venus fluorescence and
thus overrepresent Sox10 expression. To address this, a
Sox10flox-GFP mouse line in which a less stable GFP reporter is
expressed from native Sox10 transcripts was also analyzed,
and we confirmed that the majority of fetal mammary cells are
Sox10+ (Figure S3). Consistent with the Sox10-H2BVenus
whole-mount images, most single Sox10flox-GFP cells also co-ex-
pressed K8 and K14, suggesting that they may be bipotent pro-
genitors or stem cells (Figure 2F).
Stem/progenitor cell function in these Sox10+ fetal cells
was next analyzed using in vitro and in vivo stem/progenitor
cell assays. Single fMaSCs grown in 3D culture conditions
will clonally expand to generate bi-lineage organoids that
resemble the architecture of the mammary gland with innery rudiments in two different media. y axis is number of organoids per 100 cells
visualized by Sox10-H2BVenus reporter.
aSCs (columns 3 and 4), and fStroma (columns 5–7) were RNA sequenced and
d genes between fMaSC (green) and fStroma (pink).
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Figure 3. Sox10 Labels Cells with Stem/Pro-
genitor Features in Adult Mammary Tissues
(A) Immunostain for EpCAM in an adult Sox10-
H2BVenus mammary gland.
(B) FACS of Venus fluorescence (x axis) in adult
Sox10-H2BVenus luminal and basal populations
(y axis is EpCAM). Displayed are luminal cells that
were pre-gated as EpCAMhi;CD49flow-med, and
basal cells as EpCAMlow-med;CD49fhi.
(C) Venus() or Venus(+) luminal cells from an adult
Sox10-H2BVenus mammary gland cultured in 3D
for 6 days. Scale bar, 65 mm.
(D) Whole-mount immunofluorescence for K8 and
progesterone receptor (Pgr) from adult Sox10-
H2BVenusmammary glands; right image lacks Pgr
for easier visualization.
(E) Transplantation take rates for Venus()
and Venus(+) basal cells from an adult Sox10-
H2BVenus mammary gland.
(F) A reconstituted mammary gland following
transplantation of Sox10+ adult basal cells visual-
ized by the Sox10-H2BVenus reporter.K8+ luminal cells and external K14+ basal cells (Spike et al.,
2012). When E18 Sox10+ fetal cells were plated as single cells
into 3D culture conditions, they robustly formed bi-lineage
organoids (Figures 2G and 2H; Figure S3). This demonstrates
that the Sox10+ E18 population contains bipotent cells that
generate both luminal- and basal-like cells. By contrast, the
more rare Sox10neg fetal mammary cells formed spheres at
significantly reduced efficiency. As an in vivo metric of stem
cell function, E18 Sox10+ fetal cells were also transplanted
into cleared fat pads of immune-compromised mice. As
few as five Sox10+ fetal cells were sufficient to generate a2040 Cell Reports 12, 2035–2048, September 29, 2015 ª2015 The Authorsfull mammary gland, further indicating
that Sox10 positivity strongly correlates
with fMaSC activity (Figure 2I; Figure S3).
Collectively, the data demonstrate that
Sox10 expression labels cells in the fetal
mammary rudiment that possess bipo-
tent stem/progenitor features.
Notably, the organoid-forming effi-
ciency for fetal cells recovered with
the Sox10-Venus and EpCAM markers
represents a >3-fold improvement over
the original CD24 and CD49f fMaSC
marker strategy we previously em-
ployed. We isolated and RNA-sequenced
E17 Sox10+;EpCAM+ fMaSCs and their
surrounding fetal stromal cells (Table
S1). In parallel, we RNA-sequenced
E17 fMaSCs isolated by sorting for
CD24hi;CD49f+ cells to assess the purifi-
cation afforded by Sox10 and EpCAM.
Comparison of these transcriptome pro-
files revealed that numerous stromal-
associated genes were removed from
the E17 fMaSC profile by using Sox10
expression to purify fMaSCs (Figure 2J).Taken together, our data show that using Sox10 as a marker
produces an fMaSC population significantly purer than obtained
previously.
Sox10 Labels Cells with Stem/Progenitor Features in
Adult Mammary Tissues
We next analyzed Sox10 expression in the adult mammary
gland. Immunofluorescence against positional markers such
as EpCAM (high in luminal cells, low in basal cells) indicated
that Sox10 expression was more restricted in the adult gland
compared to the fetal mammary rudiment (Figure 3A). To
Figure 4. Sox10 Functionally Contributes to Stem/Progenitor Ac-
tivity in Mammary Cells
(A) Organoids from Sox10-H2BVenus fMaSCs contain Venus(+) and Venus()
cells.
(B and C) Efficiency of secondary organoid formation for Venus(+) and
Venus() cells taken from primary Sox10-H2BVenus fMaSC organoids grown
in SFM. y axis is number of secondary organoids per 100 cells plated.
(D) Representative organoid formation following 3D culture of Cre-infected
Sox10wild-type or Sox10flox/flox fMaSCs.
(E) Carmine staining of transplanted Cre-infected Sox10wild-type or Sox10flox/flox
fMaSCs into cleared fat pads. Transplants were considered takes if greater
than half the fat pad was reconstituted; * marks a partial aborted outgrowth.
Error bars represent SD.quantify the expression of Sox10 by cell type, Sox10-H2BVenus
and Sox10flox-GFP adult glands were FACS sorted into basal
and luminal fractions using EpCAM/CD49f, and the percentage
of Sox10+ cells in each fraction was then determined. These
analyses revealed that nearly all basal cells express Sox10,
whereas 50% of luminal cells express Sox10 (Figure 3B;
Figure S4).
Mammary stem/progenitor cell assays were performed on
these Sox10+ basal and luminal cells to better understand their
function in the gland. Sox10+ and Sox10neg luminal cells were
isolated by FACS and plated into 3D culture conditions. While
Sox10+ luminal cells demonstrated sphere-forming potential
with luminal characteristics (18.0 ± 2.1%), Sox10neg luminal cells
did not form spheres (0.3 ± 0.3%; Figure 3C; Figure S4). This
suggests that Sox10+ luminal cells demarcate the colony-form-Cell Reping luminal progenitor cells in the luminal fraction of the mam-
mary gland. Consistent with this, Sox10+ cells do not express
progesterone receptor, a mature luminal cell marker, which is
instead exclusively expressed in Sox10neg luminal cells (Fig-
ure 3D). In the basal cell fraction, both Sox10+ and less common
Sox10neg basal cells were transplanted into cleared fat pads to
determine MaSC function in an in vivo context. Sox10+ basal
cells exhibited robust repopulation potential, whereas no suc-
cessful transplantation was observed with Sox10neg basal cells
(Figures 3E and 3F). Sox10+ luminal cells also failed to exhibit
successful transplantation, further indicating that these are line-
age restricted progenitor cells.
These data indicate that populations with known mammary
stem/progenitor cell properties—fMaSCs in the fetal rudiment,
repopulating MaSCs in the adult basal fraction, and luminal pro-
genitors in the luminal layer of themammary gland—all appear to
express Sox10.
Sox10 Labels Cultured Mammary Cells with Stem/
Progenitor Characteristics In Vitro
The correlation of Sox10 expression with mammary stem/pro-
genitor populations in vivo led us to next investigate if Sox10
also labels cells with these properties in organoids grown
from fMaSCs in vitro. To address this, Sox10-H2BVenus
fMaSCs were grown into bi-lineage organoids in 3D culture
conditions. Intriguingly, these structures exhibited mosaic
Sox10 expression in which Sox10+ and Sox10neg cells were
clearly evident (Figure 4A). To determine if these cells differ
in stem/progenitor functionality, these populations were iso-
lated and replated into identical organoid-forming conditions
to generate secondary organoids in a classic surrogate assay
of self-renewal for stem cells. Notably, Sox10+ cells from
primary organoids had significantly greater potential to form
secondary organoids than Sox10neg cells (Figure 4B). Further,
the secondary structures from Sox10+ cells were larger and
yielded clear bi-lineage differentiation with both luminal and
basal cell types present (Figure 4C). The rare secondary out-
growths derived from Sox10neg cells were by contrast smaller
and appeared to lack the bi-lineage structure observed in
primary and Sox10+ secondary organoids (Figure 4C). These
secondary organoids appeared to show more luminal-
restricted Sox10 expression compared to primary organoids,
which may reflect the restriction in stem/progenitor compe-
tence that occurs in this differentiation medium, and may
mimic native mammary cell hierarchy. These data indicate
that in addition to mammary cells in vivo, Sox10 labels popu-
lations with enhanced stem/progenitor functions in cultured
mammary organoids in vitro.
Sox10 Functionally Contributes to Stem/Progenitor
Activity in Mammary Cells
We next determined if Sox10 actively contributes to fMaSC
function by performing stem/progenitor assays on cells in
which Sox10 expression was ablated by deletion. We infected
Sox10flox/flox and Sox10wild-type fMaSCs with Cre-expressing
lentivirus to delete Sox10 from the Sox10flox cells. While Cre-in-
fected Sox10wild-type fMaSCs generated typical organoids with
luminal and basal architecture resembling the mammary gland,orts 12, 2035–2048, September 29, 2015 ª2015 The Authors 2041
Figure 5. Ectopic Sox10 Expression Ex-
pands Stem/Progenitor Activity and Drives
Acquisition of Mesenchymal Features
(A) Primary (1) organoids from control (uninfected)
or Sox10OE m2rtTA fMaSCs were dissociated and
replated into 3D culture to form secondary (2) or-
ganoids. Shown is 2 organoid growth after 7 days.
Scale bar, 75 mm.
(B) Quantification of 2 organoid-forming potential
for Sox10OE cells compared to uninfected or
Venus-only-infected cells. y axis is # of >50 mm 2
organoids per 100 cells plated.
(C) Sox10OE fMaSCs present with satellite single
cell structures surrounding the 1 organoid (*).
Scale bar, 40 mm.
(D) Active delamination of cells from a Sox10OE
organoid.
(E) Immunostains of control or Sox10OE fMaSC
organoids demonstrate the loss of keratin
expression (red or green) in Sox10OE cells (blue).
Scale bar, 50 mm.
(F) Immunostains of Sox10OE fMaSC organoids
reveal upregulation of vimentin and loss of E-cad-
herin in Sox10OE cells (blue).
Error bars represent SD.the Cre-infected Sox10flox/flox fMaSCs generated fewer organo-
ids, and the structures that did form were typically smaller and
failed to develop the morphological features of multi-lineage or-
ganoids (Figure 4D; Figure S5).
We also performed transplantation assays with Cre-infected
Sox10flox/flox fMaSCs or Sox10flox/flox adult basal cells to deter-
mine if cells were capable of generating full outgrowths
following Sox10 deletion. No full outgrowths following trans-
plantation were observed in the Sox10null MaSCs, whereas
equivalent numbers of control cells exhibited successful
transplantation (Figure 4E; Figure S5). Together, these data
indicate that Sox10 is required for full stem/progenitor cell
functionality.
To determine if overexpression of Sox10 can increase stem/
progenitor function in mammary cells, the Tet-on system was
used to drive expression of human Sox10 in fMaSCs. fMaSCs
isolated from a mouse strain that ubiquitously expresses the
m2rtTA reverse tetracycline transactivator were infected with
either LV-TRE-hSox10-2A-NLSVenus (doxycyline [dox] in-
duces expression of Sox10 and Venus) or LV-TRE-NLSVenus
(dox induces expression only of Venus) and allowed to form
primary organoids. No apparent increase in primary organoid
formation was observed with Sox10 overexpression (Sox10OE).
These primary organoids were then dissociated to single2042 Cell Reports 12, 2035–2048, September 29, 2015 ª2015 The Authorscells, replated into identical culture
conditions, and scored for their ability
to generate secondary organoids as a
metric for increased persistence of
stem/progenitor function. While fMaSCs
that did not overexpress Sox10 showed
low ability to form secondary organoids
in differentiation medium (Figure 5A),
Sox10OE fMaSCs now demonstratedrobust secondary organoid formation (Figures 5A and 5B).
These data indicate that ectopic expression of Sox10 is able
to increase or sustain stem/progenitor competence in cultured
fetal mammary cells.
Ectopic Sox10 Expression Drives an EMT-like Response
in fMaSC-Derived Organoids
While measuring the stem/progenitor function of Sox10OE cells,
we discovered that primary organoids with Sox10OE cells
demonstrated a novel morphology in which the primary orga-
noid was surrounded by individual cells (Figure 5C). Video
microscopy showed that the satellite cells originate from the
delamination and extrusion of Sox10OE cells from the primary
organoid (Figure 5D; Movies S1 and S2). We found that
Sox10OE (Venus+) cells no longer expressed keratin markers,
suggesting that the mobility of the cells might result from
Sox10OE-induced EMT (Figure 5E; Figure S6). Sox10OE cells
also presented with additional EMT markers, including downre-
gulated expression of E-cadherin and upregulated expression
of vimentin (Figure 5F; Figure S6). No such changes were
observed in organoids not exposed to dox. These data demon-
strate that Sox10 can directly mediate an EMT-like response
when forcibly expressed at high levels in fMaSC-derived
organoids.
Figure 6. Reversal of Transient Sox10 Over-
expression Restores Epithelial Features and
Promotes Stem/Progenitor Activity
(A) Sox10OE cells were isolated from 7-day-old
fMaSC-derived primary (1) organoids and re-
plated in 3D culture ± dox. Secondary outgrowths
from these cells were immunostained for keratin
markers after 7 days.
(B) Sox10OE satellite cells form secondary (2) or-
ganoids surrounding the 1 organoid at greater
efficiency if dox is removed from the media after
4 days. Left/right are the same organoids over
10 days of culture. Scale bar, 20 mm.
(C) Sox10OE cells were allowed to form 1 orga-
noids in 3D culture for 7 days, then dox was
washed out of the media to ease Sox10 expres-
sion. 3–4 days after washout, the delaminated
satellite cells initiated 2 organoid formation (*)
around the 1 organoid.We next determined if the EMT state could be reversed in
Sox10OE mammary cells and if they retained or could regain
bipotential stem/progenitor function. Sox10OE mammary cells
were isolated from primary organoid cultures and replated into
3D culture conditions with or without dox. The Sox10OE mam-
mary cells that were plated into dox, and thus maintained high
Sox10 expression, often persisted as single cells and did not
organize into secondary organoids (Figure 6A). However, when
these same cells were plated into dox-free media, and Sox10
levels were reduced to baseline (Figure S7), the cells now
favored the formation of bi-lineage secondary organoids
(Figure 6A).
The same phenomenon was observed when Sox10OE orga-
noids that had undergone EMT and cell delamination were
subjected to a protocol that removed dox from the media
and lowered Sox10 expression to basal levels. While orga-
noids continuously exposed to dox and high Sox10 levelsCell Reports 12, 2035–2048, Sepshowed mostly persistent single-cell
satellite structures, the satellite cells in
the dox-withdrawn organoids now initi-
ated the formation of localized second-
ary organoids (Figure 6B). These sec-
ondary organoids exhibited the same
bi-lineage features of primary fMaSC
organoids, indicating that these single
Sox10OE cells have the potential to pro-
duce both luminal- and basal-like cells
(Figure 6C). Notably, this robust sec-
ondary organoid formation occurred in
the same strong differentiation media
in which cells with retained stem/
progenitor qualities are rare (Figure 4B),
indicating the downstream effects of
Sox10 serve to counterbalance these
pro-differentiation factors.
These data reveal that at high levels
of expression, Sox10 induces a mesen-
chymal transition that enables cellmigration away from primary organoids. These cells are then
capable of undergoing a mesenchymal-epithelial transition
(MET) that mediates the formation of secondary organoids,
which appears to be favored when Sox10 expression levels
are reduced.
FGF Signaling Is Required for Sox10-Induced Cell
Motility
We next attempted to identify mechanisms through which
Sox10 evokes stem/progenitor and EMT/motility functions in
mammary cells. The feedback loop between Sox transcrip-
tion factors and FGF signaling that appears to involve Sox10
and FGF10 in mammary cells (Figure 1) suggests that these
Sox10-mediated cell functions could involve FGF signaling. To
test this, fMaSCs were manipulated to overexpress Sox10 as
before, but this time in the presence of FGFRi. As expected,
fMaSCs that were given vehicle formed primary organoidstember 29, 2015 ª2015 The Authors 2043
Figure 7. FGF Signaling Is Required for
Sox10-Induced Cell Motility
(A) Sox10OE organoids were grown in 3D culture in
the presence of vehicle or 1.0 mMFGFRi. Scale bar,
100 mm.
(B) Fraction of Sox10OE organoids with extruded
satellite cells after 6 days (y axis) in the presence of
vehicle or 1.0 mM FGFRi.
(C) Sox10OE organoids were grown in 3D culture in
SFM with EGF alone or EGF, FGF2, and FGF10.
Scale bar, 40 mm.
(D) Gene Ontology terms associated with signifi-
cantly down- or upregulated genes following
Sox10OE (top) and example notable genes with
altered expression by Sox10OE (bottom).
Error bars represent SD.and the overexpression of Sox10 elicited an EMT-like delamina-
tion of cells (Figure 7A). However, this cell delamination was
significantly attenuated in organoids that were exposed to the
FGFRi, as indicated by the absence of satellite cells surrounding
the primary organoid (Figures 7A and 7B). Sox10OE organoids
that were grown in media without FGF also failed to extrude sat-
ellite cells, confirming that it is inhibition of FGF signaling by the
FGFRi that mediates this effect (Figure 7C). These data suggest
that the potentiation of FGF signaling can be one effector of
Sox10 that mediates cell delamination and that a pan-FGFRi
blocks Sox10-induced motility in fMaSC-derived mammary
organoids.2044 Cell Reports 12, 2035–2048, September 29, 2015 ª2015 The AuthorsTranscriptome Analyses of Sox10OE
Cells Indicate Potential Mediators
of Stem and EMT Functions
To more comprehensively profile the
state changes elicited by Sox10 and to
identify other potential direct or indirect
targets of Sox10 that could mediate the
stem/progenitor and EMT-like functions
of Sox10, we performed transcriptome
profiling of Sox10OE cells through RNA
sequencing (Table S2). In parallel, we
also isolated and RNA-sequenced control
organoid cells that did not overexpress
Sox10 for comparison. To assess the
quality of the sequencing data, we deter-
mined if previously described targets
of Sox10 were upregulated in response
to Sox10 overexpression. Published tar-
gets such as Mitf, Mia, and ErbB3 all
showed elevated expression in Sox10OE
cells (Bondurand et al., 2000; Graf et al.,
2014; Prasad et al., 2011) (Figure 7D).
We also analyzed targets of FGF
signaling, given our data linking Sox10
and FGF signaling. Among the targets
induced by Sox10, we found that the
FGF-positive signaling regulator Etv5
was upregulated, while the FGF negative
regulator Dusp6 was downregulated(Figure 7D). This is consistent with the positive FGF-Sox10
loop indicated by our data, in which FGF acts to induce Sox10,
while activated Sox10 then reinforces FGF signaling. These
data validate that the differential expression of molecules be-
tween Sox10OE and control cells can be used to identify targets
of Sox10 or signaling network changes initiated by Sox10.
We next identified genes that were significantly differentially
expressed in response to Sox10OE. Gene ontology analysis
with these gene lists indicated significant reprogramming of
cellular function that is consistent with the observed phenotypic
changes in Sox10OE cells (Figure 7D; Table S2). For example,
Sox10OE cells delaminate from the primary organoid where
they tend to remain quiescent, and indeed this analysis finds
genes associated with migration are upregulated with Sox10OE,
while genes associated with proliferation and adhesion are
downregulated with Sox10OE. Similarly, Sox10OE cells in organo-
ids lose differentiationmarker expression and gain stem/progen-
itor function during this process, and indeed genes associated
with differentiation are downregulated with Sox10OE. These tran-
scription data thus provide a hypothesis generating resource to
determine how Sox10 elicits important state changes in normal
or transformed mammary cells.
Notably, ErbB2 and the estrogen and progesterone hormone
receptors all showed reduced expression levels following Sox10
overexpression. Sox10 is preferentially expressed in triple-
negative breast cancers that lack these three receptors (Fig-
ure 1F). These data suggest that Sox10 may be one mechanism
of functionally specifying this triple-negative state.
DISCUSSION
Our studies have used diverse strategies to reveal important
roles for Sox10 in stem and progenitor functions within mam-
mary cells. This is first indicated by the significant correlation be-
tween Sox10 expression and two aggressive subtypes of breast
cancer that have previously been described as stem-like (basal-
like) or EMT-like (claudin-low). We then present data that Sox10
consistently labels cells with stem/progenitor qualities inmultiple
contexts that include fetal, adult, and 3D cultured mammary
tissues. Sox10 may be a cell state regulatory node in mammary
cells, as deleting Sox10 decreased stem/progenitor functions,
while its ectopic activation both expanded stem/progenitor ac-
tivity and induced EMT. This suggests that relative expression
levels of Sox10 can mediate either stem-like or EMT-like re-
sponses depending on context.
The link between Sox10 and both stem- and EMT-like cell
functions is reminiscent of the published links between CSCs
and EMT (Oskarsson et al., 2014). Importantly, it has been un-
clear to what extent CSCs are stem-like, given that their mesen-
chymal properties and transcriptome profiles often do not
resemble those of bone fide stem cells. The enhanced motility
of mesenchymalized cells may endow them with greater capac-
ity to aggregate and form polyclonal ‘‘tumorspheres’’ in suspen-
sion cultures or to invade and form tumors more efficiently in
xenograft assays. These properties are clearly independent of
stemness measured by transcription profiling, and should not
be used as surrogates for stem cell function. These concerns
have led to the rebranding of CSCs as ‘‘tumor-‘‘ or ‘‘xenograft-
initiating cells,’’ which suggests the distinction between the
stem-like cells in tumors identified transcriptionally, and the
more EMT-like CSCs.
The data described here present clear evidence that the stem
cell and mesenchymal states are related and can be intercon-
verted in stem-like cells. We find that a single factor, Sox10, is
able to contribute to cells entering each of these two states,
and critically, we show that it does so independently of the
other state. Sox10+ cells that have not undergone EMT show
increased levels of stemness in multiple contexts, while EMT oc-
curs independent of stem cell activity. The separation of these
states removes the aforementioned concerns about conflatingCell Repstemness with properties of mesenchymal cells, and demon-
strates that a single molecule such as Sox10 can link these
two distinct states. Importantly, this affirms the link between
stem-like and mesenchymal states and defines a molecular
mechanism by which these state conversions can take place.
These data also yield predictions about how mammary cells
acquire stem cell-like properties in normal and cancerous states
and how these mechanisms may contribute to metastatic dis-
ease. The capacity of Sox10 to promote both stem-like and
EMT-like behaviors suggests that Sox10 could be a factor that
mediates these two functions that are hypothesized to be
directly responsible for tumor initiation and progression. Most
notably, we have modeled the sequential stages of metastatic
behavior using only Sox10 in 3D mammary cell culture, as we
find that (1) Sox10+ cells preferably form primary organoids, (2)
Sox10OE activates EMT to elicit delamination and migration of
cells away from the primary organoid, and (3) reduction of
Sox10 levels in these cells reverses the EMT and initiates the
establishment of separate organoids at secondary sites. It is
easy to visualize how this could similarly play out in Sox10+ tu-
mors, in which microenvironmental or genomic changes could
induce fluctuations in Sox10 expression levels that cycle cells
through these stem-like and EMT states to mediate metastasis.
Our findings also have implications for how stem/progenitor
cell states may be specified in mammary cells. As discussed in
the introduction, the balanced activation of specific lineage
determining factors is a mechanism capable of mediating
stem-like functions in cells. This model fits with observations of
Sox family transcription factors, where Sox molecules have
antagonistic relationships with other factors at cell-fate decision
points. By applying this model to Sox10 and mammary cells, our
data indicate that Sox10 may specify the basal lineage in mam-
mary cells. This is apparent in the expression data, where Sox10
preferentially labels the basal cell fraction in the adult mammary
gland, and the functional data, as Sox10OE can elicit EMT in
mammary cells, and basal cells can be considered ‘‘partial
EMT’’ based on their morphology. Furthermore, this model
predicts that Sox10 should promote stem-like qualities when in
balance with other factors. This is supported by our data linking
Sox10 expression and function to stem-like properties and
our data demonstrating that lower levels of Sox10 expression
increase efficiency of bi-lineage sphere formation and self-
renewal. These data thus support a model in which cell-fate
decisions and stemness in mammary cells are regulated by a
balance of lineage specifiers, of which Sox10 is one critical
player that favors a basal lineage. However, there are pieces of
our data that do not neatly fit this model, such as that Sox10neg
cells produce mostly basal-like organoids and Sox10OE elicits
cells that appear less differentiated. This suggests that a function
of Sox10 may be to provide cell-state plasticity, instead of, or in
addition to, a role in lineage specification.
As described in the Introduction, there is not a consensus on
the localization and frequency for MaSCs. Our data and the
balanced lineage specifier model suggest that a significant
reservoir of Sox10-expressing poised basal cells exists and
that these cells could adopt activated stem/progenitor cell
properties by the acquisition of antagonistic factors that bring
Sox10 levels into an equilibrium that favors a stem cell state.orts 12, 2035–2048, September 29, 2015 ª2015 The Authors 2045
This is consistent with work that indicates the majority of single
basal cells have the potential to generate full mammary glands
(Prater et al., 2014). Evaluating this model will require a better
understanding of how Sox10 works in concert with other, pre-
sumably pro-luminal factors, such as Elf5, Gata3, and Notch
signaling, among others. Similarly, it will be key to evaluate
the relationship of Sox10 with basal lineage regulators such
as p63 and Slug and the stem-cell marker Lgr5 (Oakes et al.,
2014).
Finally, two of our most striking results are that the use of an
FGFR inhibitor profoundly affects the expression of Sox10 and
the delamination phenotype induced through Sox10OE. Notably,
the deletion of FGFR1 and FGFR2 results in the loss of the
transplantation competent population of mammary stem cells
and compromises ductal remodeling, which mirror the roles for
Sox10 in stem cell competence and cell motility shown here
(Pond et al., 2013). Extrinsic signaling mechanisms in the stem
cell niche that regulate the frequency and output of stem cells
are potential targets for cancer prevention or treatment. Thus,
it will be key to determine if blocking FGF signaling also antago-
nizes the expression or downstream effects of Sox10 (or other
Sox family transcription factors) in vivo in normal mammary
tissue or tumors. Together, these data imply a central role for
FGF signaling and Sox10 in normal mammary function and indi-
cate that tight control is required to prevent it from eliciting
malignant functions.
EXPERIMENTAL PROCEDURES
Mice
Mice were housed in accordance with NIH guidelines in Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC)-ac-
credited facilities at the Salk Institute. All experimental protocols were
approved by the Salk Institute Institutional Animal Care and Use Committee.
Mammary Cell Preparation
Single-cell preparations of fetal mammary cells were obtained by pooling
freshly dissected fetal mammary rudiments from euthanized embryos into
dissociation media (Epicult-B Basal medium [STEMCELL Technologies] sup-
plemented with 5% fetal bovine serum [FBS], penicillin/streptomycin, fungi-
zone, hydrocortisone, collagenase, and hyaluronidase). Rudiments were
then dissociated to single cells by sequentially incubating them in dissociation
medium for 1.5 hr at 37C with gentle agitation, exposing them to ammonium
chloride for 4 min on ice to remove erythrocytes and triturating them with
dispase and DNase. Final suspensions were passed through a 40-mm filter
to remove aggregated cells and stored in Hank’s balanced salt solution with
2% FBS for flow cytometry. Single-cell preparations of adult mammary cells
were made by dissecting out and mincing the #4 mammary glands from
6- to 12-week-old virgin female mice. Glands were then dissociated by
agitating them for 3–6 hr at 37C in the same dissociation media. Cells were
further processed as with the fetal cells, except that trypsin and Accutase
(Life Technologies) were also utilized prior to dispase treatment to facilitate
disaggregation. Final suspensions were passed through a 40-mm filter to re-
move cell clusters and stored in Hank’s balanced salt solution with 2% FBS
for flow cytometry.
Immunostaining and Confocal Analyses
Mammary tissues were immunostained through direct or indirect immuno-
fluorescence. Confocal microscopy was performed with equipment from the
Waitt Advanced Biophotonics Center at the Salk Institute, including Zeiss 780
inverted laser scanning confocal microscopes. Details of tissue preparation
and staining protocol are included in Supplemental Experimental Procedures.2046 Cell Reports 12, 2035–2048, September 29, 2015 ª2015 The A3D Organoid Culture
To generate organoids, single mammary cells were plated at 50–650
cells per well in 96-well ultra low-adhesion plates (Costar) with Matrigel.
Cells were plated in either restricted serum-free media (Epicult-B media
with B-supplement [STEMCELL Technologies] containing heparin and
penicillin/streptomycin and defined growth factors such as EGF, FGF2,
and/or FGF10) or in serum-based MCF10A media (DMEM/F12 with 5%
horse serum, hydrocortisone, cholera toxin, insulin, and ciproflaxin, sup-
plemented with B27 supplement and EGF). Description of the plating
protocol and analysis of these cells is in Supplemental Experimental
Procedures.
4D Organoid Culture and Imaging
m2rtTA fMaSCswere infected with LV-TRE-hSox10-2A-NLSVenus and plated
onto glass-bottom 35-mm dishes with a Matrigel bed in restricted serum-free
media. After 72 hr, organoidswere given freshmedia and dox to induce Sox10/
Venus expression. 8–24 hr later, cells were imaged at 10-min intervals with a
Zeiss CSU Spinning Disk Confocal Microscope in a climate-controlled envi-
ronment of 5% CO2 and 37
C. Images were assembled into movies using
Imaris imaging software.
RNA Sequencing and Bioinformatic Analyses
RNA isolation, sequencing, and analysis are described in detail in Supple-
mental Experimental Procedures.
Statistical Analyses
A two-tailed Student’s t test was used to quantify significance. p values were
represented as follows: *p < 0.05, **p < 0.005, ***p < 0.0001.
Additional experimental procedures are described in Supplemental Experi-
mental Procedures.
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The accession number for the RNA-sequencing data reported in this paper is
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